MARKET WIREReuters • 32m ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Why IMA Stock dropped -3.57% Today — RQD Quant Desk Flash
$4.05 -3.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.02
ImageneBio Inc. (IMA) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $46.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ImageneBio Inc. (NASDAQ: IMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.05 (-3.57% 1D, market cap $46.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMA ranks #1001 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMA compare to LONA and TIL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMA carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, IMA leads on earnings multiple (N/A) while IMA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMA?
▼
Per IMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835579), ImageneBio Inc. generated $800.0K in revenue (-77.1% YoY), -$45.3M in net income, and -$47.8M in free cash flow against $153.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.02 (-0.83%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMA)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY IMA SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (37% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.6 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.25-5.9% Next Q
27
Q2 (-2Q)Grade E$4.00+1.2% Next Q
24
Q3 (-1Q)Grade E$4.05+0% Next Q
22
CurrentGrade E$4.05-12% Hist 90D α
19
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMA Turnaround Squeeze
While IMA currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.64) and Max Pain ($4.25) forces dealer call-delta covering toward $9.28.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMA Stock dropped -3.57% Today — RQD Quant Desk Flash
ImageneBio Inc. (IMA) dropped -3.57% to $4.05, trading at 3% of its 52-week range ($3.88 – $8.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($3.88 – $8.84) with RSI-14 at 38.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $4.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMA Headlines & Catalysts
MARKET WIREReuters • 2h ago
Gold rises on softer oil; Markets parse Fed signals - ReutersGold rises on softer oil; Markets parse Fed signals Reuters
CATALYSTReuters • 5h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
CATALYSTReuters • 7h ago
Bank of England poised to raise rates but may push back on bets for more - ReutersBank of England poised to raise rates but may push back on bets for more Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Oil prices ease 3% on optimism for Qatari-led talks on ending Iran war - ReutersOil prices ease 3% on optimism for Qatari-led talks on ending Iran war Reuters
MARKET WIREReuters • 9h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 11h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMA)
- ✓Walkthrough of IMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.20%▼ DESCENDING CHANNEL
2026-11-02O $4.20H $4.20L $4.05C $4.05VOL 4.7K
RES: $6.03SUP: $3.52SMA50: $4.64SMA200: $5.62
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMA)
Health Care Rank #1001 of 1016
⚔️ LONA vs IMA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMA vs. LONA, TIL, INMB, CRBU)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ImageneBio Inc. (IMA) ranks #1001 by composite RQD confidence (19/100, grade E) and #762 by equity capitalization ($46.0M). Within this direct 5-issuer industry benchmark cohort, IMA leads on earnings valuation at N/A trailing P/E, while IMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with IMA at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMA
ACTIVE
ImageneBio Inc. | E | 19/100 | — | — | -35.0% | -3.57% | $46.0M | Benchmark Subject |
| LONA LeonaBio Inc. | D- | 36/100 | — | — | -35.0% | -1.01% | $46.3M | /lona-vs-ima → |
| TIL Instil Bio Inc. | D- | 39/100 | — | — | -35.0% | +0.52% | $46.3M | /til-vs-ima → |
| INMB INmune Bio Inc. | E | 31/100 | — | — | -35.0% | +4.58% | $44.4M | /inmb-vs-ima → |
| CRBU Caribou Biosciences Inc. | E | 33/100 | — | — | -35.0% | -9.07% | $47.7M | /crbu-vs-ima → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835579In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImageneBio Inc. (IMA) reported GAAP revenue of $800.0K (-77.1% vs. FY2024 revenue of $3.5M , and -91.3% cumulative change since FY2023) , GAAP net income of -$45.3M, operating cash flow of -$47.8M, and free cash flow of -$47.8M (-124.4% YoY). On the balance sheet, IMA closed FY2025 with $153.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $800.0K | -$45.3M | -$47.8M | -$47.8M | $153.0M | — |
| FY2024 (FY) | 2024-12-31 | $3.5M | -$36.6M | -$21.3M | -$21.3M | $15.9M | — |
| FY2023 (FY) | 2023-12-31 | $9.2M | -$68.2M | -$79.7M | -$79.7M | — | — |
3. IMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ImageneBio Inc. (NASDAQ: IMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.05 (-3.57% 1D, market cap $46.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMA ranks #1001 in composite RQD confidence.
How does IMA compare to LONA and TIL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMA carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, IMA leads on earnings multiple (N/A) while IMA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMA?
Per IMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835579), ImageneBio Inc. generated $800.0K in revenue (-77.1% YoY), -$45.3M in net income, and -$47.8M in free cash flow against $153.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMA trading relative to its 50-day, 200-day, and 52-week technical levels?
IMA last traded at $4.05 (-3.57% on volume of 4,654 shares), positioning the stock -12.72% below its 50-day simple moving average ($4.64) and -27.94% below its 200-day simple moving average ($5.62). Across its 52-week range of $3.88 to $8.84, IMA sits at the 3.4% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($3.58 to $4.52).
IMA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMA stock moving today?
Why IMA Stock dropped -3.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.